Background: A meta-analysis was conducted to evaluate the accuracy of whole-body positron emission tomography (PET) and PET-CT in initial M staging of head and neck cancer.
Methods: After a systematic review of English language studies, sensitivity, specificity, and other measures of whole-body PET and PET-CT were pooled. Summary receiver operating characteristic (SROC) curves were also used to summarize overall test performance.
Results: Eight PET and 7 PET-CT studies were identified. The pooled sensitivity estimates for PET and PET-CT were 0.848 (95% confidence interval [CI], 0.776-0.905) and 0.875 (95% CI, 0.787-0.936). The pooled specificity estimates were 0.952 (95% CI, 0.933-0.967) and 0.950 (95% CI, 0.931-0.964). The Q* index estimates for PET-CT (0.9409) were not significantly higher than for PET (0.9154; p > .05).
Conclusion: Whole-body PET and PET-CT have good diagnostic performance in initial M staging of head and neck cancer; although PET-CT tends to have higher accuracy than PET.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.21400 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Utility of F-FDG PET/CT metabolic parameters on post-transplant lymphoproliferative disorder diagnosis.
Ann Nucl Med
January 2025
Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, 300052, China.
Objective: Using F-FDG PET/CT metabolic parameters to differentiate post-transplant lymphoproliferative disorder (PTLD) and reactive lymphoid hyperplasia (RLH), and PTLD subtypes.
Methods: F-FDG PET/CT and clinical data from 63 PTLD cases and 19 RLH cases were retrospectively collected. According to the 2017 WHO classification, PTLD was categorized into four subtypes: nondestructive (ND-PTLD), polymorphic (P-PTLD), monomorphic (M-PTLD), and classic Hodgkin.
Are we underestimating pathological fracture risk in malignant bone lesions of the proximal humerus?
Skeletal Radiol
January 2025
Department of Trauma, Hand and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747, Jena, Germany.
Objective: This study is aimed at evaluating the distribution of metastatic bone disease (MBD), with a particular focus on the humerus, and its association with pathological fractures. Factors for contributing to the underestimation of fracture risk were assessed, including their impact on surgical management.
Materials And Methods: We retrospectively reviewed patient records of patients undergoing surgical treatment for MBD at our institution between 2005 and 2023.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Clin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
[F]FDG PET/CT versus Dynamic Contrast-Enhanced CT for the diagnosis of solitary pulmonary Nodule: A Head-to-Head comparative Meta-Analysis.
Eur J Radiol
January 2025
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, 030032, China; Department of Pulmonary and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, 030032, China; Department of Pulmonary and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Electronic address:
Purpose: This head-to-head comparative meta-analysis aimed to evaluate the comparative diagnostic efficacy of [F]FDG PET/CT and dynamic contrast-enhanced CT(DCE-CT) for the differentiation between malignant and benign pulmonary nodules.
Methods: An extensive search was conducted in the PubMed, Embase, and Web of Science to identify available publications up to March 23, 2024. Studies were included if they evaluated the diagnostic efficacy of [F]FDG PET/CT and DCE-CT for the characterization of pulmonary nodules.
Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer.
J Zhejiang Univ Sci B
January 2025
Department of Orthopedics, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
Prostate cancer is the second most common cancer in men, accounting for 14.1% of new cancer cases in 2020. The aggressiveness of prostate cancer is highly variable, depending on its grade and stage at the time of diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!